Stupp protocol — Temozolomide concurrent + adjuvant
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TEMOZOLOMIDE |
|---|
| ID | REG-STUPP-TMZ |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-EANO-GBM-2024 SRC-NCCN-CNS-2025 |
Notes
Stupp 2005: TMZ + RT 60 Gy / 30 fx → mOS 14.6 vs 12.1 mo RT-only. Long-term: 5-yr OS 9.8% vs 1.9%. MGMT-methylated subgroup: mOS 21.7 vs 15.3 mo. RT 60 Gy / 30 fractions concurrent NOT modellable per PROPOSAL §17. This regimen entry captures TMZ chemo only. Elderly (≥70) with poor PS: TMZ-only (Nordic / Wick) or RT-only (CCTG CE.6 hypofractionated 40 Gy / 15 fx + TMZ for ≥65) are acceptable Stupp variations — separate regimen entries TBD.
Used By
Indication
IND-GBM-NEWLY-DIAGNOSED-STUPP- IND-GBM-NEWLY-DIAGNOSED-STUPP